Opioid receptor active compounds
    11.
    发明授权
    Opioid receptor active compounds 失效
    阿片受体活性化合物

    公开(公告)号:US07776898B2

    公开(公告)日:2010-08-17

    申请号:US11857193

    申请日:2007-09-18

    IPC分类号: A61K31/4196 C07D249/08

    摘要: The invention provides compounds of formula I: wherein R1 to R4 and n have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating pain and treating other conditions which involve, for example, binding opioid receptors using compounds of formula I.

    摘要翻译: 本发明提供式I化合物:其中R 1至R 4和n具有本说明书中定义的任何含义及其药学上可接受的盐。 本发明还提供包含式I化合物的药物组合物,制备式I化合物的方法,可用于制备式I化合物的中间体,以及用于治疗疼痛和治疗其它病症的治疗方法,所述治疗方法涉及例如使用 式I化合物。

    Method and device for frame interpolation of a moving image
    12.
    发明授权
    Method and device for frame interpolation of a moving image 失效
    运动图像帧插值的方法和装置

    公开(公告)号:US5410358A

    公开(公告)日:1995-04-25

    申请号:US185833

    申请日:1994-03-24

    IPC分类号: H04N7/01 H04N7/26

    CPC分类号: H04N7/014 H04N19/00 H04N19/20

    摘要: Apparatus and method for forming an interpolated image corresponding to a given temporal distance ratio between a first and a second image including respectively, a first image in which the first and second images include a first and a second 3-D shape model of an object having respective shading values and that there is a 3-D motion vector defining the transformation between the first and the second 3-D shape models. The method includes: a) adjusting the interpolation 3-D motion vector (Vab) to obtain an interpolation 3-D motion vector (vi); b) forming an interpolation 3-D shape model (Mi) from the interpolation 3-D motion vector (Vi) and either the first or the second 3-D shape model (Ma,Mb); and c) forming an interpolation image from the interpolation 3-D shape model and the image shaping values from the first and second 3-D shape models. The invention provides a method and apparatus for frame interpolation of a moving image which remedies block-shaped distortion in interpolated frames, and which can reproduce smooth movement even when the input image includes movement in 3-dimensional space.

    摘要翻译: PCT No.PCT / GB92 / 01344 Sec。 371日期1994年3月24日 102(e)1994年3月24日PCT提交1992年7月22日PCT公布。 出版物WO93 / 02529 日期:1993年2月4日。用于形成对应于第一和第二图像之间的给定时间距离比的内插图像的装置和方法,分别包括第一图像,其中第一和第二图像包括第一和第二3- 具有各个着色值的对象的D形模型,并且存在定义第一和第二3D形状模型之间的变换的3维运动矢量。 该方法包括:a)调整内插3-D运动矢量(Vab)以获得插值3-D运动矢量(vi); b)从插值3-D运动矢量(Vi)和第一或第二3D形状模型(Ma,Mb)中形成插值3-D形状模型(Mi); 以及c)从所述插值3-D形状模型和来自所述第一和第三3D形状模型的图像整形值形成内插图像。 本发明提供一种用于补偿内插帧中的块状失真的运动图像的帧内插的方法和装置,并且即使当输入图像包括在三维空间中的运动时,其也可以再现平滑的运动。

    Estrogen receptor modulators and uses thereof
    15.
    发明授权
    Estrogen receptor modulators and uses thereof 失效
    雌激素受体调节剂及其用途

    公开(公告)号:US07989487B2

    公开(公告)日:2011-08-02

    申请号:US12307565

    申请日:2007-07-06

    IPC分类号: A61K31/40 A61K31/12

    摘要: A method for preventing, diagnosing, or treating a condition mediated by an estrogen receptor by administering to a patient in need thereof an effective amount of a compound of formula I, II, or a combination thereof: wherein R1, R3, R4, and R5 are independently selected from H, OH, and ORa; R2 is selected from H, OH, and (C═O)(C1-7)alkyl; Ra is (C1-7)alkyl or (C═O)(C1-7)alkyl; or a derivative of the compound selected from N-oxide derivatives, prodrug derivatives, protected derivatives, isomers, and mixtures of isomers of the compound; or a pharmaceutically acceptable salt or solvate of the compound or the derivative. Compounds of formula I and II and pharmaceuticals compositions thereof are also presented.

    摘要翻译: 一种通过向有需要的患者施用有效量的式I,II化合物或其组合来预防,诊断或治疗由雌激素受体介导的病症的方法,其中R1,R3,R4和R5 独立地选自H,OH和ORa; R2选自H,OH和(C = O)(C 1-7)烷基; R a为(C 1-7)烷基或(C = O)(C 1-7)烷基; 或选自所述化合物的N-氧化物衍生物,前药衍生物,保护的衍生物,异构体和异构体混合物的化合物的衍生物; 或化合物或其衍生物的药学上可接受的盐或溶剂化物。 还提供了式I和II的化合物及其药物组合物。

    Computer Aided Ligand-Based and Receptor-Based Drug Design Utilizing Molecular Shape and Electrostatic Complementarity
    17.
    发明申请
    Computer Aided Ligand-Based and Receptor-Based Drug Design Utilizing Molecular Shape and Electrostatic Complementarity 失效
    基于计算机辅助配体和基于受体的药物设计利用分子形态和静电互补

    公开(公告)号:US20110066384A1

    公开(公告)日:2011-03-17

    申请号:US12904968

    申请日:2010-10-14

    IPC分类号: G06F19/00

    摘要: Methods related to the generation of shape signatures representing molecular shape, and using shape signatures in both ligand-based and receptor-based molecular design. Ray-tracing is used to explore the volume interior to a ligand, or the space exterior to a receptor site. Shape signatures are then probability distributions derived from the ray-traces. Shape signatures provide condensed descriptors of shape properties readily compared to each other to test for shape similarity or complementarity.

    摘要翻译: 与代表分子形状的形状特征的产生相关的方法,以及基于配体和受体的分子设计中的形状特征。 光线跟踪用于探索配体内部的体积,或受体位点外部的空间。 形状特征就是衍射自射线轨迹的概率分布。 形状特征提供形状特征的简明描述,容易相互比较,以测试形状相似性或互补性。

    Glutamate receptor modulators and therapeutic agents
    18.
    发明申请
    Glutamate receptor modulators and therapeutic agents 失效
    谷氨酸受体调节剂和治疗剂

    公开(公告)号:US20090239919A1

    公开(公告)日:2009-09-24

    申请号:US12381086

    申请日:2009-03-06

    摘要: The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. Diseases and disorders contemplated include, inter alia, diseases and disorders of the central nervous system, the peripheral nervous system, the gastrointestinal system, the circulatory system, skin, retina, brain, heart, and lungs.

    摘要翻译: 本发明公开了使用确定类型的苯甲酰胺化合物调节I组mGluR的活性的方法。 在一个实施方案中,提供调节mGluR1活性的方法。 在另一个实施方案中,提供调节mGluR5活性的方法。 在另一个实施方案中,提供了同时调节mGluR1和mGluR5的活性的方法。 本发明还提供了使用一种或多种属于所定义类型的苯甲酰胺化合物的化合物来治疗全部或部分由I组mGluR介导的疾病或病症的方法。 本发明还提供了使用一种或多种属于所定类化合物的化合物来预防全部或部分由I组mGluR介导的疾病或病症的方法。 预期的疾病和障碍尤其包括中枢神经系统,周围神经系统,胃肠系统,循环系统,皮肤,视网膜,脑,心脏和肺的疾病和病症。